Did Research Solutions beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Research Solutions year over year?

What were the key takeaways from Research Solutions’s earnings call?

What is the market's earnings forecast for Research Solutions next quarter?

What were the key takeaways from Research Solutions's earnings call?

What is Research Solutions's latest dividend and current dividend yield?

What is Research Solutions's gross profit margin?

What does Research Solutions do and what are its main business segments?

- **B2B Infrastructure Growth**: 14% ARR rise to $21.8M, 47 new deployments, 2-5x larger API deals.
- **AI-Driven Innovation**: 1M+ API calls/year, AI-powered research tools, AI adoption improving dev/productivity.
- **Financial Resilience**: $1.3M EBITDA (+36% YoY), $12.3M cash, no debt.
- **Challenges**: B2C conversion down 2%, but investing in new data features.
- **2026H2 Outlook**: Exceed 2025Q2 EBITDA, 20%+ SaaS growth return.

**【Management Opening Remarks】**
- Q2 2026 revenue decline due to one churned account and larger customer volume reductions, but B2B ARR grew 14% to $15.3M, driven by 47 new platform deployments.
- Management emphasizes B2B annual agreements and API integrations as primary growth drivers, with B2C conversion challenges due to increased competition.

**【CEO Summary Section】**
- B2B ARR up 14% YoY, with 2-5x larger API deals embedding RSSS into customer infrastructure.
- Transitioning from document delivery to Answers and Access platform, with 1M+ API calls/year and AI-powered research tools.
- B2C trial-to-subscriber conversion rate down 2%, but investing in new data features (patents, clinical trials) to improve retention.

**【CFO Financial Commentary】**
- Q2 2026: $11.8M revenue (-1% YoY), $5.2M platform revenue (+14%), $21.8M ARR (+14% YoY).
- Gross margin 52.4% (up 350bps YoY), operating expenses $5.4M (-5.6% YoY), net income $0.55M vs. $0.07M loss YoY.
- Adjusted EBITDA $1.3M (+36% YoY), cash flow from ops $1.4M, no debt, $12.3M cash.

**【Q&A Highlights】**
- B2B pipeline growing with API deals; B2C expects 2026H2 stability via quality over growth focus.
- AI adoption internally improving dev/productivity, but not yet cost-saving; external AI partnerships with Claude/ChatGPT for cited research.
- Publisher MCP discussions for long-tail content access, with 100+ API calls/day from pharma customers.
- 2026H2 targets: exceed 2025Q2 EBITDA, 20%+ SaaS growth return, $12.3M cash balance, no debt.


Research Solutions, Inc. (RSSS) Q2 2026 Earnings Call Transcript

- **ARR Growth Record**: Total ARR up 21% to $21.3 million, with B2B ARR driving 88% of growth.
- **AI Rights Innovation**: New RightsDel product targets 50% ARR uplift for platform business, with early-stage adoption.
- **Financial Strength**: 50.6% gross margin, $1.5 million EBITDA (16% YoY growth), and $1.1 million operating cash flow.
- **Strategic Focus**: B2B expansion with 1:1 ARR ROI, B2C-to-B2B pipeline of $1 million, and AI-driven efficiency gains.
- **Risks**: Transaction revenue decline from 3 large customers, B2C conversion challenges.

**【CEO Summary Section】**
- **Record ARR Growth**: Total ARR reached $21.3 million, up 21% YoY, driven by B2B ARR of $14.8 million and B2C ARR of $6.5 million. Notable deals include a new platform sale to a top 10 pharma company.
- **AI Strategy Momentum**: Introduced AI rights product (RightsDel) for enterprises to acquire AI usage rights on research articles, with potential to uplift ARR by 50% for the platform business.
- **B2B Expansion**: New logo teams generated $1 in new ARR for every dollar invested, with ASPs increasing due to better sales execution.
- **B2C to B2B Pipeline**: Over 1 million pipeline dollars originated from B2C users transitioning to enterprise subscriptions.

**【CFO Financial Commentary】**
- **Revenue Performance**: Total revenue $12.3 million (+2.5% YoY), platform subscription revenue $5.1 million (+18% YoY). Transaction revenue $7.2 million (-6.5% YoY) due to 3 large customers reducing spend.
- **Profitability**: Gross margin 50.6% (vs 47.9% YoY), driven by higher platform gross margin (88.1%). Adjusted EBITDA $1.5 million (+16% YoY), second-highest on record.
- **Cash Flow**: Operating cash flow $1.1 million (+31% YoY). Cash balance $12 million post $1.3 million Scite earnout payment.
- **Cost Control**: G&A expenses down 12%, offsetting higher sales & marketing spend.

**【Q&A Key Highlights】**
- **AI Attach Rate**: Early-stage product with no clear attach rate yet, but potential 50% ARR uplift for platform business.
- **B2C Strategy**: Focused on improving conversion from 7-day trial to paid subscription, with AI-driven product enhancements.
- **Transaction Outlook**: Q2 decline expected to be less severe than Q1, with academic segment growth offsetting corporate churn.
- **Internal AI Adoption**: Accelerating development efficiency with AI tools, with plans to implement AI in support functions.
- **M&A Pipeline**: Active discussions, but no closures expected by year-end.


Research Solutions, Inc. (RSSS) Q1 2026 Earnings Call Transcript

- **ASP Growth Acceleration**: Sequential ASP increase driven by 4x growth in AI-related deals and multi-hundred thousand dollar contracts.
- **Resolute API Integration**: Leveraging 13 databases via API to become a key data provider for LLMs, creating sticky enterprise integrations.
- **Margin Expansion**: EBITDA margin >10% in FY26, gross margin >50%, supported by AWS cost optimization and AI provider discounts.
- **AI-Driven Expansion**: Unique position as neutral content aggregator enables 4x growth in AI deals, targeting enterprise-wide AI tool integrations.
- **Transaction Business Turnaround**: Focused on improving conversion rates through AI recommendations, aiming to reverse document sales decline.

**【ASP Growth and Sales Strategy】**
- Sequential ASP increase driven by larger deals (e.g., recent multi-hundred thousand dollar contracts), improved sales execution, and recovery from prior Resolute-related churn.
- Focus on API-first deals with LLMs, leveraging 13 highly curated databases to embed into customer workflows, creating sticky contracts.

**【Resolute and API Strategy】**
- Resolute's headless API architecture positions it as a key data provider for AI integrations, with 13 databases now accessible via API.
- Strategy involves selling data directly to LLMs and enterprises, bypassing traditional UI constraints.

**【Competitive Landscape】**
- Uniquely positioned as a neutral aggregator of publisher content, unlike competitors who restrict access to their own content.
- Observing other publishers (e.g., third-largest in the world) beginning to open content to LLMs, but scale and ecosystem integration give RSSS an edge.

**【Cost Optimization and Margins】**
- COGS decline through AWS prepayments (reducing hosting costs by ~10%), AI provider cost reductions, and stable labor expenses.
- EBITDA margin expected to remain above 10% in FY26, with gross margin >50%.

**【AI-Driven Deal Growth】**
- AI-related deals growing 4x faster than non-AI, driven by B2B API integrations priced per usage rather than per-seat.
- Larger deal sizes in B2B due to enterprise-wide AI tool integrations.

**【Large Deal Dynamics】**
- $100k+ deals fueled by new sales process focusing on customer pain points and value-based pricing, plus academic segment pricing experiments.
- Cross-sell penetration between Site and Article Galaxy remains low (mid-single digits), but strategic focus area.

**【Transactions Business Strategy】**
- Decline in document sales attributed to AI替代部分查询需求, with ~10% of customers reducing purchases.
- Plan to improve conversion rates via AI-driven recommendations (e.g., suggesting related articles post-purchase), similar to Amazon's approach.


Research Solutions (RSSS)-18 Sep 25-2025 Q4 Earnings call transcript

- **ARR Milestone Achieved**: Q3 ARR surpasses $20M, up 23% YoY, driven by 43 net new deployments.
- **AI Growth Dominant**: B2B AI ARR grows 180% YoY, with Scite Assistant adding multi-model support and TABLES mode for data extraction.
- **Financial Strength**: Record $1.4M EBITDA (67% YoY growth), 49.5% gross margin, and $2.9M Q3 cash flow.
- **Sales Momentum**: New logo teams drive 50%+ bookings, with upsell team achieving best quarter on record.
- **AI Efficiency Push**: Internal AI adoption focuses on R&D productivity, with plans to automate customer reporting.


**【CEO Opening Remarks】**
- Q3 revenue growth driven by strong ARR bookings, with net new deployments of 43 (12-month trailing total: 150). ARR surpasses $20 million for the first time, up 23% YoY.
- AI-based products show exceptional growth: B2B enterprise license segment ARR grows 180% YoY. AI strategy is proving successful in addressing customer needs for trustworthy research tools.
- Sales and marketing investments are yielding results, with higher average deal sizes and improved close rates across all sales teams.

**【CFO Financial Highlights】**
- Total Q3 revenue: $12.7M (22% YoY growth in platform subscription revenue to $4.8M). Platform revenue now 38% of total, up from 33% YoY.
- Gross margin improves to 49.5% (430 bps YoY), driven by higher-margin SaaS revenue mix. Platform gross margin: 87.4% (180 bps YoY), transaction margin: 26% (30 bps YoY).
- Adjusted EBITDA sets new record at $1.4M (67% YoY growth), with trailing 12-month EBITDA margin of 10.4%. Cash flow from operations: $2.9M Q3, $6.7M LTM.
- Operating expenses increase 5% YoY, with 90% of growth allocated to sales and marketing. Net income: $216K ($0.01 EPS), up from $76K YoY.

**【Josh Nicholson - AI Strategy Update】**
- Scite Assistant now supports multiple LLM models and introduces TABLES mode for data extraction. B2B customers benefit from exclusive AI features, including hallucination mitigation.
- Academic partnerships expand: 2 new publishers added to Article Galaxy, 8 publishers signed for AI rights. Scite recognized as finalist in Society of Scholarly Publishing EPIC Awards.
- AI-driven workflows enhance research efficiency, enabling users to verify claims and assess article relevance with full-text previews.

**【Q&A Key Takeaways】**
- **Growth Strategy**: CEO targets predictable sales model for B2B, with potential to scale investments if metrics justify. Rule of 40 progress: 34.1% Q3, 33.1% LTM.
- **AI Internal Use**: Focus on AI as productivity tool for R&D, with plans to automate reporting for Tier 3 accounts. Microsoft-style code generation initiatives in early stages.
- **Sales Team Performance**: New logo teams account for >50% Q3 bookings. Upsell team achieves best quarter on record, cross-selling Scite to Article Galaxy customers.
- **B2C Seasonality**: Trial and signup trends align with academic calendar, but Q3 changes improved conversion rates despite seasonal softness.


Research Solutions (RSSS)-8 May 25-2025 Q3 Earnings call transcript

- **Record ARR growth**: $1.5M net new ARR vs. $19.1M total ARR (+23% YoY). 
- **Margin expansion**: Gross margin 48.9% (up 540bps YoY), EBITDA $0.96M (+200% YoY). 
- **Scite success**: 75% YoY growth driven by 61 new Platform deployments. 
- **AI cost efficiency**: 50% reduction in AI spend since integration. 
- **Seasonality warning**: B2C slowdown expected in Q4 academic break period.

**【CEO Opening Remarks】**
- Q2 net new ARR growth of $1.5 million, driven by 61 net Platform deployments (highest organic performance in company history). 
- Academic and corporate sales teams performed strongly post-reorganization, but churn and upsell remain areas for improvement.
- B2C ARR growth slowed in December due to holiday season, expected to rebound in Q3.

**【CFO Financial Highlights】**
- Total revenue $11.9M (+15.5% YoY), with Platform subscription revenue at $4.6M (+47% YoY). 
- ARR reached $19.1M (+23% YoY), with 39% of revenue from high-margin Platforms business. 
- Gross margin improved 540bps to 48.9%, driven by Platform scale. 
- Operating expenses $5.7M (+16% YoY) due to sales & marketing investments. 
- Adjusted EBITDA $0.96M (+200% YoY), cash flow from ops $1M. 

**【Josh Nicholson - AI Strategy】**
- Differentiated by vertical focus on research workflows + exclusive access to scientific content. 
- AI cost efficiency improved 50% since integration, with ongoing model optimization. 
- Cross-selling Scite into Article Galaxy base driving incremental ARR growth. 

**【Q&A Key Takeaways】**
- 75% of Q2 Scite growth from new logos vs. cross-sells. 
- B2C seasonality: Q2/Q3 strong, Q4 slowdown due to academic breaks. 
- AI costs expected to remain stable with model efficiency gains. 
- Earn-out liability of $2.4M to be paid 50/50 cash/stock over 8 quarters starting Q3. 
- Total shares outstanding ~32.6M as of filing date.

Actual					0.01	0.01	-0.01	-0.02	-0.01	-0.02	0.01	-0.01	0.01	0.01	-0.04	0.02	0	-0.09	0.02	-0.07	0.0252	0.07	0.02	0.02
Forecast						0	-0.01	-0.01	-0.015	-0.01	0	0.005	0.005	0.015	-0.02	0	0.0167	-0.06	0.0167	0.02	0.0309	0.0533	0.0318	0.03
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	+33.33%	-100.00%	0.00%	-300.00%	+100.00%	-33.33%	-100.00%	0.00%	-100.00%	-50.00%	+19.76%	-450.00%	-18.45%	+31.33%	-37.11%	-33.33%

RSSS

RSSS fundamentals

RSSS Q2 2026 Earnings

Earnings Call

You can ask Aime

RSSS

RSSS fundamentals

RSSS Q2 2026 Earnings

Earnings Call

RSSS Earnings Call Summary for Q2/20265:00 PM on Feb 12, 2026

RSSS Earnings Call Summary for Q1/20265:00 PM on Nov 13, 2025

RSSS Earnings Call Summary for Q4/20255:00 PM on Sep 18, 2025

RSSS Earnings Call Summary for Q3/20255:00 PM on May 8, 2025

RSSS Earnings Call Summary for Q2/20255:00 PM on Feb 13, 2025

You can ask Aime